FIELD: medicine.
SUBSTANCE: presented herein are methods of treating polycystic kidney disease, including autosomal-dominant polycystic kidney disease, using modified oligonucleotides aimed at miR-17.
EFFECT: methods of treating polycystic kidney disease are disclosed.
36 cl, 4 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALPORT SYNDROME TREATMENT OPTIONS | 2018 |
|
RU2791694C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
| OLIGONUCLEOTIDE CONJUGATES | 2013 |
|
RU2653438C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| CLOSED-END LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER | 2017 |
|
RU2752882C2 |
| SUBSTANCES AND METHODS OF MODULATING TENDON HEALING | 2015 |
|
RU2699706C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| VERSIONS OF RECOMBINANT AAV AND USE THEREOF | 2015 |
|
RU2738421C2 |
